Viking Therapeutics: The Turning Point Is Not Here Yet
Viking Therapeutics investors face challenges as stock plummets, cash runway helps but betting on early stage biopharma ...
2 Companies Poised to Capitalize on the Rise of GLP-1 Drugs
The market for GLP-1 drugs is projected to exceed $200 billion in annual sales by 2031, according to Morningstar Equity Research. Current market leaders include Novo Nordisk NVO and Eli Lilly LLY with ...
Study Shows Diabetes Drugs' Potential Beyond Weight Loss
A new study highlighted Monday the potential benefits of popular diabetes drugs on a wide range of health issues including dementia and cardiovascular diseases, although experts warned against seeing ...
Hosted on MSN17h
NVO Stock Down as Medicare Selects Semaglutide Drugs for Price Cuts
Novo Nordisk’s NVO shares lost 5.3% on Friday after Medicare issued a press release selecting the company’s popular ...
Sweeping review suggests weight-loss drugs’ effect on 175 conditions
The findings, based on an analysis of records from 2.5 million VA patients, support much of what scientists already suspected ...
Popular GLP-1 medications may have health benefits that extend beyond weight loss and blood sugar control, a new study finds
Popular GLP-1 medications approved for weight loss, diabetes, and heart disease may have untapped potential to reduce the ...